经皮机械循环支持辅助经皮冠状动脉介入治疗后的早期再入院:来自全国再入院数据库的见解。

IF 1.6 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
Sean DeAngelo, Badri Aryal, Gianfranco Bittar-Carlini, Rohan Gajjar, Jeremiah Bello, Sharan Malkani, Ufuk Vardar, Abhimanyu Saini
{"title":"经皮机械循环支持辅助经皮冠状动脉介入治疗后的早期再入院:来自全国再入院数据库的见解。","authors":"Sean DeAngelo, Badri Aryal, Gianfranco Bittar-Carlini, Rohan Gajjar, Jeremiah Bello, Sharan Malkani, Ufuk Vardar, Abhimanyu Saini","doi":"10.1016/j.carrev.2025.06.002","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The use of percutaneous mechanical circulatory support (pMCS)-assisted percutaneous coronary intervention (PCI) has seen an increase in use over the past five years. It remains unclear how the increased prevalence has affected the rate of readmissions and what clinical predictors may play a role in a patient's readmission. We aimed to assess the cardiovascular causes, mortality rate, and clinical predictors of patients readmitted after experiencing pMCS-assisted PCI.</p><p><strong>Methods: </strong>Patients who underwent pMCS (intra-aortic balloon pump, Impella, or percutaneous left ventricular assist device) and PCI between January 2016 and November 2020 were selected from the nationwide readmission database. The frequency and underlying causes of cardiovascular-related 30-day readmissions were assessed, as delineated by the International Classification of Diseases, Tenth Revision (ICD-10) codes. Additionally, readmission mortality rates, mean hospital stay length, cumulative hospital charges, and independent factors predictive of 30-day all-cause readmissions were analyzed. A secondary analysis of mortality and readmission rate in patients with cardiogenic shock who underwent pMCS were compared to those with pMCS-assisted PCI.</p><p><strong>Results: </strong>Of the 77,099 patients discharged alive after receiving pMCS-assisted PCI, 12,072 (15.6%) had a readmission within 30 days. Among the readmissions, the all-cause mortality was 876 (7.26%). The most common cardiovascular causes for readmission were hypertensive heart disease with heart failure (8.6%), hypertensive heart and chronic kidney disease stage 1-4 (8.3%), and non-ST elevation myocardial infarction (4.1 %). Readmitted patients exhibited a shorter mean length of stay in contrast to their index admission (5.9 vs 9.9 days, p < 0.0001). Patients who were readmitted incurred total hospital charges of $1.01 billion US. Factors independently associated with 30-day readmissions were female sex, leaving against medical advice, renal insufficiency, congestive heart failure, prior valve replacement, and length of stay > 10 days. Index mortality was significantly higher in the pMCS-assisted cardiogenic shock cohort compared the pMCS-assisted PCI group (32.6% vs 26.4%; CI: 5.8-6.6, p < 0.001). Readmission rate was significantly higher in the pMCS-assisted cardiogenic shock cohort compared the pMCS-assisted PCI group (16.4% vs 15.7 %; CI: 0.4-1.1, p < 0.001).</p><p><strong>Conclusion: </strong>Our study revealed that 15.6% of patients discharged after receiving pMCS-assisted PCI were readmitted within 30 days, with an all-cause mortality rate of 7.26% among these readmissions. The most common causes of readmission were related to hypertensive heart disease and NSTEMI. These findings underscore the need for targeted interventions to reduce readmissions and associated healthcare costs, as well as the importance of identifying high-risk patients for more intensive follow-up and management after discharge from pMCS-assisted PCI.</p>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Early readmissions after percutaneous mechanical circulatory support-assisted percutaneous coronary intervention: Insights from the nationwide readmissions database.\",\"authors\":\"Sean DeAngelo, Badri Aryal, Gianfranco Bittar-Carlini, Rohan Gajjar, Jeremiah Bello, Sharan Malkani, Ufuk Vardar, Abhimanyu Saini\",\"doi\":\"10.1016/j.carrev.2025.06.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The use of percutaneous mechanical circulatory support (pMCS)-assisted percutaneous coronary intervention (PCI) has seen an increase in use over the past five years. It remains unclear how the increased prevalence has affected the rate of readmissions and what clinical predictors may play a role in a patient's readmission. We aimed to assess the cardiovascular causes, mortality rate, and clinical predictors of patients readmitted after experiencing pMCS-assisted PCI.</p><p><strong>Methods: </strong>Patients who underwent pMCS (intra-aortic balloon pump, Impella, or percutaneous left ventricular assist device) and PCI between January 2016 and November 2020 were selected from the nationwide readmission database. The frequency and underlying causes of cardiovascular-related 30-day readmissions were assessed, as delineated by the International Classification of Diseases, Tenth Revision (ICD-10) codes. Additionally, readmission mortality rates, mean hospital stay length, cumulative hospital charges, and independent factors predictive of 30-day all-cause readmissions were analyzed. A secondary analysis of mortality and readmission rate in patients with cardiogenic shock who underwent pMCS were compared to those with pMCS-assisted PCI.</p><p><strong>Results: </strong>Of the 77,099 patients discharged alive after receiving pMCS-assisted PCI, 12,072 (15.6%) had a readmission within 30 days. Among the readmissions, the all-cause mortality was 876 (7.26%). The most common cardiovascular causes for readmission were hypertensive heart disease with heart failure (8.6%), hypertensive heart and chronic kidney disease stage 1-4 (8.3%), and non-ST elevation myocardial infarction (4.1 %). Readmitted patients exhibited a shorter mean length of stay in contrast to their index admission (5.9 vs 9.9 days, p < 0.0001). Patients who were readmitted incurred total hospital charges of $1.01 billion US. Factors independently associated with 30-day readmissions were female sex, leaving against medical advice, renal insufficiency, congestive heart failure, prior valve replacement, and length of stay > 10 days. Index mortality was significantly higher in the pMCS-assisted cardiogenic shock cohort compared the pMCS-assisted PCI group (32.6% vs 26.4%; CI: 5.8-6.6, p < 0.001). Readmission rate was significantly higher in the pMCS-assisted cardiogenic shock cohort compared the pMCS-assisted PCI group (16.4% vs 15.7 %; CI: 0.4-1.1, p < 0.001).</p><p><strong>Conclusion: </strong>Our study revealed that 15.6% of patients discharged after receiving pMCS-assisted PCI were readmitted within 30 days, with an all-cause mortality rate of 7.26% among these readmissions. The most common causes of readmission were related to hypertensive heart disease and NSTEMI. These findings underscore the need for targeted interventions to reduce readmissions and associated healthcare costs, as well as the importance of identifying high-risk patients for more intensive follow-up and management after discharge from pMCS-assisted PCI.</p>\",\"PeriodicalId\":47657,\"journal\":{\"name\":\"Cardiovascular Revascularization Medicine\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2025-06-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cardiovascular Revascularization Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.carrev.2025.06.002\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Revascularization Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.carrev.2025.06.002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

背景:在过去的五年中,经皮机械循环支持(pMCS)辅助经皮冠状动脉介入治疗(PCI)的使用有所增加。目前尚不清楚患病率的增加是如何影响再入院率的,以及哪些临床预测因素可能在患者再入院中发挥作用。我们的目的是评估pmcs辅助PCI后再入院患者的心血管原因、死亡率和临床预测因素。方法:从全国再入院数据库中选择2016年1月至2020年11月期间接受pMCS(主动脉内球囊泵、Impella或经皮左心室辅助装置)和PCI治疗的患者。根据国际疾病分类第十版(ICD-10)代码,评估了心血管相关的30天再入院的频率和潜在原因。此外,还分析了再入院死亡率、平均住院时间、累计住院费用和预测30天全因再入院的独立因素。对经pMCS辅助PCI与经pMCS辅助PCI的心源性休克患者的死亡率和再入院率进行了二次分析。结果:77,099例患者在接受pmcs辅助PCI治疗后存活出院,其中12,072例(15.6%)在30天内再次入院。再入院患者全因死亡率为876例(7.26%)。再入院最常见的心血管原因是高血压心脏病合并心力衰竭(8.6%)、高血压心脏和慢性肾脏疾病1-4期(8.3%)和非st段抬高型心肌梗死(4.1%)。再入院患者的平均住院时间比首次入院患者短(5.9天vs 9.9天,p 10天)。与pmcs辅助PCI组相比,pmcs辅助心源性休克组的指数死亡率显著高于pmcs辅助PCI组(32.6% vs 26.4%;结论:我们的研究显示,15.6%接受pmcs辅助PCI术后出院的患者在30天内再次入院,其中全因死亡率为7.26%。再入院最常见的原因与高血压心脏病和非stemi有关。这些发现强调了有针对性的干预措施的必要性,以减少再入院和相关的医疗保健费用,以及识别高风险患者,在pmcs辅助PCI出院后进行更深入的随访和管理的重要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Early readmissions after percutaneous mechanical circulatory support-assisted percutaneous coronary intervention: Insights from the nationwide readmissions database.

Background: The use of percutaneous mechanical circulatory support (pMCS)-assisted percutaneous coronary intervention (PCI) has seen an increase in use over the past five years. It remains unclear how the increased prevalence has affected the rate of readmissions and what clinical predictors may play a role in a patient's readmission. We aimed to assess the cardiovascular causes, mortality rate, and clinical predictors of patients readmitted after experiencing pMCS-assisted PCI.

Methods: Patients who underwent pMCS (intra-aortic balloon pump, Impella, or percutaneous left ventricular assist device) and PCI between January 2016 and November 2020 were selected from the nationwide readmission database. The frequency and underlying causes of cardiovascular-related 30-day readmissions were assessed, as delineated by the International Classification of Diseases, Tenth Revision (ICD-10) codes. Additionally, readmission mortality rates, mean hospital stay length, cumulative hospital charges, and independent factors predictive of 30-day all-cause readmissions were analyzed. A secondary analysis of mortality and readmission rate in patients with cardiogenic shock who underwent pMCS were compared to those with pMCS-assisted PCI.

Results: Of the 77,099 patients discharged alive after receiving pMCS-assisted PCI, 12,072 (15.6%) had a readmission within 30 days. Among the readmissions, the all-cause mortality was 876 (7.26%). The most common cardiovascular causes for readmission were hypertensive heart disease with heart failure (8.6%), hypertensive heart and chronic kidney disease stage 1-4 (8.3%), and non-ST elevation myocardial infarction (4.1 %). Readmitted patients exhibited a shorter mean length of stay in contrast to their index admission (5.9 vs 9.9 days, p < 0.0001). Patients who were readmitted incurred total hospital charges of $1.01 billion US. Factors independently associated with 30-day readmissions were female sex, leaving against medical advice, renal insufficiency, congestive heart failure, prior valve replacement, and length of stay > 10 days. Index mortality was significantly higher in the pMCS-assisted cardiogenic shock cohort compared the pMCS-assisted PCI group (32.6% vs 26.4%; CI: 5.8-6.6, p < 0.001). Readmission rate was significantly higher in the pMCS-assisted cardiogenic shock cohort compared the pMCS-assisted PCI group (16.4% vs 15.7 %; CI: 0.4-1.1, p < 0.001).

Conclusion: Our study revealed that 15.6% of patients discharged after receiving pMCS-assisted PCI were readmitted within 30 days, with an all-cause mortality rate of 7.26% among these readmissions. The most common causes of readmission were related to hypertensive heart disease and NSTEMI. These findings underscore the need for targeted interventions to reduce readmissions and associated healthcare costs, as well as the importance of identifying high-risk patients for more intensive follow-up and management after discharge from pMCS-assisted PCI.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Cardiovascular Revascularization Medicine
Cardiovascular Revascularization Medicine CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
3.30
自引率
5.90%
发文量
687
审稿时长
36 days
期刊介绍: Cardiovascular Revascularization Medicine (CRM) is an international and multidisciplinary journal that publishes original laboratory and clinical investigations related to revascularization therapies in cardiovascular medicine. Cardiovascular Revascularization Medicine publishes articles related to preclinical work and molecular interventions, including angiogenesis, cell therapy, pharmacological interventions, restenosis management, and prevention, including experiments conducted in human subjects, in laboratory animals, and in vitro. Specific areas of interest include percutaneous angioplasty in coronary and peripheral arteries, intervention in structural heart disease, cardiovascular surgery, etc.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信